scholarly article | Q13442814 |
P356 | DOI | 10.2215/CJN.00120605 |
P698 | PubMed publication ID | 17699197 |
P2093 | author name string | Antonio Guasch | |
James A Tumlin | |||
Randolph Hennigar | |||
Danlyn Miller | |||
Mitzi Near | |||
Sasi Selvaraj | |||
P433 | issue | 1 | |
P921 | main subject | sirolimus | Q32089 |
focal segmental glomerulosclerosis | Q1435223 | ||
P304 | page(s) | 109-116 | |
P577 | publication date | 2005-11-30 | |
P1433 | published in | Clinical Journal of the American Society of Nephrology | Q15757929 |
P1476 | title | A prospective, open-label trial of sirolimus in the treatment of focal segmental glomerulosclerosis | |
P478 | volume | 1 |
Q35056271 | Advances in the biology and genetics of the podocytopathies: implications for diagnosis and therapy |
Q89838674 | Current understandings in treating children with steroid-resistant nephrotic syndrome |
Q64106685 | Inhibiting 4E-BP1 re-activation represses podocyte cell cycle re-entry and apoptosis induced by adriamycin |
Q41812610 | Inhibition of MTOR disrupts autophagic flux in podocytes |
Q41787297 | Is There a Role for Mammalian Target of Rapamycin Inhibition in Renal Failure due to Mesangioproliferative Nephrotic Syndrome? |
Q33571758 | Low-dose rapamycin (sirolimus) effects in autosomal dominant polycystic kidney disease: an open-label randomized controlled pilot study |
Q37828086 | New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome |
Q37218108 | Nonimmunosuppressive effects of mammalian target of rapamycin inhibitors |
Q57151742 | Pathology of Calcineurin and Mammalian Target of Rapamycin Inhibitors in Kidney Transplantation |
Q37760379 | Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases |
Q37251705 | Remission of proteinuria in primary glomerulonephritis: we know the goal but do we know the price? |
Q53028092 | Rituximab: is replacement of cyclophosphamide and calcineurin inhibitors in steroid-dependent nephrotic syndrome possible? |
Q38914374 | Roles of mTOR complexes in the kidney: implications for renal disease and transplantation. |
Q36674174 | Sirolimus-associated proteinuria and renal dysfunction |
Q38922365 | Targeting mTOR Signaling Can Prevent the Progression of FSGS. |
Q50210828 | The Akt/mTOR/p70S6K pathway is activated in IgA nephropathy and rapamycin may represent a viable treatment option |
Q35614311 | Therapeutic approach to FSGS in children |
Q26752836 | Treatment Strategies of Adult Primary Focal Segmental Glomerulosclerosis: A Systematic Review Focusing on the Last Two Decades |
Q37218125 | mToR inhibitors-induced proteinuria: mechanisms, significance, and management |
Search more.